ALK Biomarkers
Pfizer's Xalkori Gets FDA Approval for ALK-Positive Inflammatory Myofibroblastic Tumors
The agency approved the drug to treat both adult and pediatric patients with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.
Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC
The trial will enroll 90 never-smoker patients with advanced NSCLC harboring alterations in MET exon 14, ALK, EGFR, or NTRK.
Mass General Program to Help Doctors Balance End-of-Life Talks With Precision Oncology Optimism
Premium
High expectations for targeted therapies make metastatic lung cancer patients hopeful, but they need support once they progress or run out of targeted therapy options.
ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential
Premium
Researchers urged other oncologists to look for ALK rearrangements in GI patients and try to get them on ALK inhibitors through trials or compassionate use programs.
Xcovery's Ensartinib Approved for First-Line ALK-Positive NSCLC in China
The drug was previously approved in the country as a second-line treatment for ALK-positive non-small cell lung cancer patients.